Journal
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
Volume 69, Issue 3, Pages 373-376Publisher
SPRINGER HEIDELBERG
DOI: 10.1007/s00228-012-1379-2
Keywords
Spice; K2; Synthetic cannabinoid receptor agonist; SCRA; AM-2201; Recreational drugs; Cannabis
Categories
Ask authors/readers for more resources
Purpose There is increasing reported use of synthetic cannabinoid receptor agonists (SCRA) across Europe. To date, there is limited information on the acute toxicity (harm) related to the use of these products. We describe here a case in which an individual developed convulsions related to the use of the SCRA AM-2201. Case report A 20 year old male smoked a Spice (SCRA-containing) product called Black Mamba, and rapidly after smoking, he had a generalised self-terminating tonic-clonic convulsion. After a 2 h observation period in the Emergency Department (ED), he self-discharged against medical advice. Subsequent analysis of urine collected at the time of presentation to the ED detected metabolites of AM-2201; no other drugs were detected on extensive analytic screening. Discussion This is the first case of convulsions related to the use of SCRA described in Europe, and the first case of convulsions related to the use the SCRA AM-2201 confirmed by analysis of biological samples. It is important for emergency physicians, clinical toxicologists and clinical pharmacologists managing those presenting with acute toxicity related to the use of SCRA to analytically confirm the exact compound(s) involved, to enable accurate description of the acute toxicity associated with individual SCRA.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available